Healthcare
Nanobiotix S.A.(NBTX)
Live Price
Offline$36.27
+0.55% today
1Y Change
+626.22%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $1.39B
- Revenue Growth
- +512.3%
- EPS Growth
- +65.3%
- Dividend Yield
- 0.0%
Coverage: 249 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nanobiotix S.A. (NBTX) is a Healthcare stock with a market cap of $1.39B and listed on NASDAQ. The stock last traded around $36.27 and up 626.2% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +512.3%, EPS growth of +65.3%, a dividend yield of 0.0%. What stands out right now is revenue +512.3%, EPS +65.3%, free cash flow -66.5% with operating margin -36.5% and ROIC -74.3%. Valuation already assumes a fairly strong business story at price/sales 46.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NBTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+512.3% vs +7.6% peer median
Operating Margin
Below sector median
-36.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on Mar 31, 2026 with an EPS surprise of -250.7% and a revenue surprise of -93.2%.
The operating story is still moving forward
Revenue is running at +512.3% and EPS at +65.3%, with operating margin around -36.5%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 30, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +4.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | -250.7% | +10.4% | -0.2% | +6.9% |
2025 Sep 30, 2025 | +45.9% | -0.8% | +11.0% | -6.7% |
2025 Apr 2, 2025 | -63.5% | -4.3% | +3.0% | +44.0% |
Benchmark Edge
NBTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NBTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NBTX Max Drawdown
-50.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NBTX and SPY.
Company Overview
Nanobiotix S.A.
NASDAQ Global Select
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
- Leadership
- Laurent Levy
- IPO Date
- Dec 11, 2020
- Employees
- 108
- Street Address
- 60 rue de Wattignies
- Mailing
- Paris, 75012
- Region
- Paris, FR
- Reporting Currency
- USD
- Investor Line
- 33 1 40 26 04 70
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 46.9
- Price/Book
- โ
Growth
- Revenue
- +512.3%
- EPS
- +65.3%
- Free Cash Flow
- -66.5%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -36.5%
- Net Margin
- -80.8%
- ROE
- 31.2%
- ROIC
- -74.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.